Immediate Impact
1 by Nobel laureates 46 standout
Citing Papers
The role of m6A methylation in therapy resistance in cancer
2023 Standout
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
2022 Standout
Works of C. Tosello being referenced
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
2015
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
1997
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| C. Tosello | 77 | 42 | 22 | 9 | 94 | |
| B. Valenza | 66 | 30 | 34 | 9 | 90 | |
| Pierfrancesco Cadenelli | 35 | 22 | 18 | 11 | 88 | |
| J. Douma | 84 | 24 | 19 | 8 | 96 | |
| Fernando Palacios Salas | 155 | 75 | 48 | 14 | 184 | |
| Thomas H. Openshaw | 97 | 104 | 37 | 12 | 183 | |
| A. Pelegrí | 116 | 96 | 43 | 11 | 205 | |
| Xichun Hu | 133 | 30 | 51 | 9 | 176 | |
| D. Perroni | 137 | 76 | 40 | 10 | 199 | |
| Hiroki Kamata | 76 | 19 | 18 | 10 | 166 | |
| José Rodrigo Espinosa Fernández | 41 | 23 | 10 | 9 | 61 |
All Works
Login with ORCID to disown or claim papers
Loading papers...